

U.S. Ser. No. 10/627,014
Filed : July 25, 2003

REMARKS

In the Official Action mailed January 3, 2007, a species election was requested on the claims of Group I, which were elected in Applicant's response filed 23 October 2006. The Examiner indicated that the claims of Group I contain claims directed to the following species

(1) Various compounds that stimulate an increase in central dopaminergic neuronal activity as set forth in claims 4 and 5; and

(2) Various compounds that stimulate a decrease in central noradrenergic neuronal activity level set forth in claims 8 and 9.

With respect to compounds that stimulate an increase in central dopaminergic neuronal activity (Item 1 above), Applicant herein elects without traverse post synaptic dopamine receptor agonist compounds as set forth in claim 4, and more specifically, apomorphine as set forth in claim 5.

With respect to compounds that stimulate a decrease in central noradrenergic neuronal activity level (item 2 above), Applicants believe that claims 7 and 8 were intended and not claims 8 and 9. Applicant herein elects without traverse inhibitors of noradrenalin synthesis as set forth in claim 7, and more specifically, fusaric acid as set forth in claim 8.

U.S. Ser. No. 10/627,014
Filed : July 25, 2003


Applicant submits that these elections read on pending
claims 1-14.

If the Examiner has any questions concerning this
application, she is encouraged to contact the undersigned
attorney.

Please charge any fees due with this response to Deposit
Account 23-1665 under Customer Number 27267.

Respectfully submitted,

ANTHONY H. CINCOTTA

By 

Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

WIGGIN and DANA LLP
One Century Tower
New Haven, CT 06508
Telephone: (203) 498-4400
Fax: (203) 782-2889

Date: 05 MAR 2007

\\1554615\\640042.1